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Abstract
Background: Understanding of the impact of non-structured treatment interruption (TI) and variation in tablet-taking on
failure of first-line antiretroviral therapy (ART) is limited in a resource-poor setting.
Methods: A retrospective matched case-control analysis. Individuals failing ART were matched by time on ART with 4
controls. Viral load (VL) and CD4 count were completed 4-monthly. Adherence percentages, from tablet returns, were
calculated 4-monthly (interval) and from ART start (cumulative). Variation between intervals and TI (.27 days off ART) were
recorded. Conditional multivariate logistic regression analysis was performed to estimate the effect of cumulative
adherence ,90%, at least one episode of adherence variation .10% and TI on virological failure. Age, gender, baseline log
VL and CD4 were included as possible confounders in the multivariate model.
Results: 244 patients (44 cases, 200 controls) were included. Median age was 32 years (IQR28–37), baseline CD4 108 cells/
mm3 (IQR56–151), VL 4.82 log (IQR4.48–5.23). 94% (96% controls, 86% failures) had cumulative adherence .90%. The odds
of failure increased 3 times (aOR 3.01, 95%CI 0.81–11.21) in individuals with cumulative adherence ,90%, 2.2 times (aOR
2.20, 95%CI 1.04–4.64) in individuals with at least one episode of fluctuating adherence of .10% and 4.01 times (aOR 4.01,
95%CI 1.45–11.10) in individuals with TIs. For individuals with TI and cumulative adherence .95%, the odds of failing were
5.65 (CI 1.40–22.85).
Conclusion: It is well known that poor cumulative adherence increases risk of virological failure, but less well understood
that TI and variations in tablet-taking also play a key role, despite otherwise excellent adherence.
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Introduction
Whilst the connection between adherence and virological
outcomes is well established, there remains more to be understood
about how patterns of adherence shape those outcomes [1]. As
antiretroviral treatments have developed, so has the understanding
about how much adherence is required for treatment success. [2–
4]. Much effort has been put into patient education and adherence
programs to help patients attain high adherence targets. Despite
this, patient adherence is still often characterised by missed doses,
fluctuation in adherence and treatment interruptions (TIs), the
impact of which needs to be understood in order to provide good
clinical care. [5–7] Missed doses and TIs have been a recent topic
of interest in the literature, but limited studies, particularly from
sub-Saharan Africa, have examined the impact on virological
outcome [5,8,9].
Treatment interruptions may be structured or non-structured.
Structured treatment interruptions, or provider-guided alternat-
ing periods of being on and off treatment, are harmful and are
not recommended [10–12]. Non-structured treatment interrup-
tions are unplanned, and the period without exposure to
antiretroviral therapy varies. They may be initiated by a doctor
e.g. due to toxicity or poor adherence, or by a patient e.g. due to
pill fatigue or a side effect. These treatment interruptions are the
reality of patient and doctor behavior although they are likely to
cause harm. TIs are known to predict drug resistance [8], disease
progression [13,14], viral rebound [15], and failure [16]. As
more is understood about the type and impact of TIs, the more
attuned the interventions to prevent these breaks in therapy may
become.
This retrospective, case-control study examines the impact of
poor or varying tablet taking behavior (when in possession of
ART) and lack of drug exposure through a treatment
interruption on the risk of failure of first-line antiretroviral
therapy in a resource-poor ART clinic in Cape Town, South
Africa.
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Setting
The study was conducted at the Hannan-Crusaid Treatment
Centre (HCTC) in the Klipfontein health sub-district, Cape
Town, South Africa. This is a predominately low-income urban
community that is home to an estimated 420 000 people in mid-
2010 with an ante-natal HIV prevalence rate of 24% noted in
2009.[17] The HCTC has provided antiretroviral therapy (ART)
for paediatric and adult patients since September 2002.
Patients at the HCTC were serviced by a multi-disciplinary
team and ART was dispensed according to the South African
National ART guidelines [18]. All patients were commenced on a
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
regimen, usually with stavudine (d4T) and lamivudine (3TC).
Patients attended at least twice for scheduled visits prior to
commencing ART and then at weeks 0, 4, 8, and 16 on treatment,
with regular 4-monthly follow-up thereafter. CD4 count and HIV
RNA [using the branch DNA hybridisation technique Bayer HIV-
1 RNA 3.0 assay (branch DNA)] were completed before starting
ART and every 16 weeks thereafter. Virologic failure was defined
as two consecutive viral load values .1,000 copies/mL, with a
subsequent switch to second line treatment. Safety tests were also
conducted according to the South African National ART
guidelines [18].
All patients were required to attend a three-session treatment
preparedness class, with at least two sessions to be completed
before ART was commenced. Each patient was encouraged to
disclose to someone in their social support network, to assist them
with treatment adherence. At the first clinic visit a peer counsellor
was assigned to each patient. The counsellor provided education
support, home visits, and liaised with the clinical team. At least one
home visit was conducted pre-ART and another in the first 4
weeks on ART. Further home visits were conducted as necessary.
At 4-monthly scheduled visits, and every 4 to 8 weeks in
between, tablet returns were counted and an adherence percent-
age calculated. These were typically done by the peer counsellors
with review by the clinicians. Any decrease in adherence to
,85%, or any on-treatment viral load .50 copies/ml, triggered a
stepped-up adherence intervention including an individual tailored
adherence counselling session, provision and instruction on use of
a pill box, monthly home visits and the reduction of the ART
dispensing window to one month only. This intensive intervention
continued until adherence percentage improved and viral load was
again ,50 copies/ml.
Study Population and Design
ART naı ¨ve adults (.15 years) starting ART at the Hannan-
Crusaid Treatment Centre between September 2002 and
February 2007 were eligible for this study. A retrospective
matched case-control analysis was performed. Cases included
patients experiencing virological failure (2 consecutive viral loads
.1000 copies/ml). Time to failure was time from initiation of
ART to date of confirmatory viral load .1000 copies/ml.
Controls were selected randomly from all non-failure patients in
the cohort, and were matched to the cases by time on ART. One
case was matched to 4–5 controls to form a unit.
Demographic data and laboratory measurements (viral load and
CD4 counts) were extracted from the HCTC electronic patient
database. This access database is updated weekly and validated
every 3 months. Tablet return data (date of visit, number of tablets
returned per medication and number of tablets dispensed at the
visit) were copied from each patients clinic record and adherence
percentages were recalculated for each patient by the study team,
using the formula below.
Adherence(%)~
(Number of tablets dispensed  number of tablets returned)
(Date tablets returned  date tablets dispensed)  Number of tablets per day
Adherence Measures and Definitions
Interval adherence calculated patient’s adherence in 4-month
intervals i.e. from one scheduled visit to the next using the
formula above [Figure 1]. One patient may have multiple interval
adherence percentages e.g. weeks 0–16, 16–32, 32–48, etc. Data
must have been available for at least 28 days of a 16 week period
for an interval adherence percentage to be generated. Interval
adherence excluded time when patients were off treatment, i.e.
periods of treatment interruption, and gave an estimate of tablet-
taking behaviour while in possession of ART.
On occasions when tablet return data was missing due to absent
pharmacy records but it was clear from the clinical notes that the
patient was still in care and taking medication, the mean of the
adherence for the remaining weeks of the interval was used.
Cumulative adherence captured the mean adherence from start of
ART to point of failure or matched duration of ART for controls
[Figure 1]. This was calculated as a mean on the interval
adherence values available for each patient. This measure
averaged out adherence over the total time in question but
excluded time when the patients were off treatment due to
treatment interruptions. Each patient only has one cumulative
adherence percentage. For the purposes of analysis the adherence
percentages were treated as categorical variables. Cumulative
adherence was analysed as $95% vs. ,95%; and again as $90%
vs. ,90%.
Variation in adherence was the absolute value of the difference
between one interval adherence percentage and that of the
subsequent interval. A patient would have multiple adherence
variation percentages [figure 1], but were categorised into those
with at least one difference between consecutive adherence
intervals of $10%, or not, for analysis purposes.
Treatment interruptions were defined as any period of time off
treatment for 28 days or more whether initiated by clinical staff or
by the patient. Treatment interruption was categorized into either
‘‘no TI’’ or ‘‘one or more TI’’. For sensitivity analysis treatment
interruptions were further categorized into patient initiated
treatment interruptions and doctor initiated interruptions. The
latter were further classified into TIs due to toxicity or not.
Statistical Analysis
Conditional logistic regression analysis was conducted using Stata
(version 11, College Station, Texas). Univariate analysis was
performed investigating the effect of cumulative adherence ,95%,
of cumulative adherence ,90%, at least one variation of adherence
of more than 10% and treatment interruption. Multivariate
conditional logistic regression models were used to estimate odds
ratios adjusting for potential confounders defined a priori using the
following variables: age, gender, baseline viral load and baseline
CD4 cell count. Sensitivity analyses were conducted excluding
treatmentinterruptionsduetotoxicityanddoctorinitiatedtreatment
interruptions. The effect of treatment interruption was further
investigated while adjusting for cumulative adherence.
Ethics
The University of Cape Town Ethics Committee has approved
collection and collation of clinical data collected routinely at the
ART Treatment Interruption and Viral Failure
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clinic signs an informed consent document to this end.
Results
Patient Sample
By February 2007, 2,871 patients had started first-line ART at
the Hannan Crusaid Treatment Centre. Only 59 patients had
experienced virologic failure at this point.
Of the 59 patients who failed treatment, 44 met eligibility
requirements (naı ¨ve adults .15 years). These 44 cases were
matched to 200 controls. The majority were female (n=180,
73.8%) and median age at initiation of treatment was 32 years
(IQR 28–37), see Table 1. Most patients had symptomatic HIV
disease and were commencing ART with at low CD4 counts), see
table 1. Median time to failure was 64 weeks (IQR 48–88 weeks).
All patients were commenced on NNRTI based regimens, with
three patients switched to a regimen containing a protease
inhibitor (lopinavir/r) due to NNRTI toxicity. Only 26 of 953
intervals contained missing data (2.7%). 72% of the missing tablet
count data occurred due to a period of extreme staff shortage from
March to November 2004.
Median cumulative adherence was 97.8% for controls and
96.6% for failures. The majority (81.9%) of all study patients had a
cumulative adherence $ 95%, whilst only 0.8% had a cumulative
adherence below 80%, see table 2. Ninety-six percent of controls
had adherence $90%, compared to 86.3% of the failures.
Of the 244 patients, 21 (8.6%) interrupted treatment at least
once, and there were 23 treatment interruptions in total. The
median length of interruption was 79 days (IQR 47–137). There
was a median of 186 days (IQR 63–309) from the end of the TI to
confirmed virological failure. The majority of the patient-initiated
treatment interruptions were related to travelling away from home
for an extended period or to non-disclosure of HIV status to those
at home. Doctor-initiated treatment interruptions were largely due
to drug-related toxicity, or extremely poor adherence noted on pill
count (,75%).
Association between adherence variables and failure
Univariate analyses showed that a cumulative adherence of
,95%, cumulative adherence of ,90%, at least one episode of
adherence variation of $10% and at least one episode of
treatment interruption increased the odds of failure by 2.09
(95%CI 0.93–4.70), 4.50 (1.31–15.48), 2.07 (95%CI 1.01–4.24)
and 4.42 (1.67–11.70) respectively, see table 3. Adjustment for
potential confounders revealed similar results. A reduction of
cumulative adherence to ,90% increased the odds of failing by
three times, (adjusted odds ratio (aOR) 3.01 (95%CI 0.81–11.21),
whereas at least one episode of variation of .10% resulted in a
two times increased odds of failing (aOR 2.20 (95%CI 1.04–4.64)
Figure 1. Schematic depicting different adherence measures used.
doi:10.1371/journal.pone.0023088.g001
Table 1. Baseline patient characteristics at time of ART initiation.
Patients (n) Total population (n=244) Controls (n=200) Failures (n=44) p-values
Age: years 32 (28–37) 32 (28–38) 31 (27–34) 0.0642
Female: n (%) 180 (73.8%) 147 (73.5%) 33 (75.0%) 0.838
WHO Stage: n (%)
Stage III 127 (52.1%) 107 (53.5%) 20 (45.5%) 0.343
Stage IV 67 (27.5%) 51 (25.5%) 16 (36.4%)
CD4 cell count (cells/mL) 108 (56–152) 115 (69–156) 49 (15–103) ,0.001
HIV-1 Viral Load,
log10 copies/mL
4.82 (4.48–5.23) 4.78 (4.43–5.22) 5.00 (4.68–5.52) 0.041
Values are given as median (IQR), unless otherwise stated.
doi:10.1371/journal.pone.0023088.t001
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(95%CI 1.45–11.10). The effect estimate did not change when
treatment interruption due to toxicity or doctor initiated treatment
interruptions were excluded. Furthermore, adjusting for all
potential confounders and cumulative adherence ,95% resulted
in an aOR of 3.24 (95% 1.03–10.20) for treatment interruption.
For a person who had a treatment interruption and a cumulative
adherence .95%, the odds of failing treatment were 5.65 (CI
1.40–22.85). The effect of a treatment interruption in individuals
with cumulative adherence ,95% could not be determined as
there were very few individuals with cumulative adherence ,95%.
Discussion
While it is well-known that poor adherence to ART is key to
treatment failure, it is less well understood that treatment
interruptions may play as important a role as tablet-taking
behaviour. Parienti et al found that treatment interruptions for
NNRTIs at low to moderate levels of adherence pose a greater risk
of viral rebound than the same number of interspersed missed
doses. [1] This study confirms findings of others outside of and
within the African context [9,16], that treatment interruptions can
lead to virologic failure.
The new information gained from this study is that the above
results hold even when controlling for suboptimal adherence. Thus
even patients who keep their cumulative adherence above 95%
may not recover from a single treatment interruption of .28days,
and proceed to fail treatment. Treatment interruptions are thus
not simply a proxy for poor adherence and may reflect a group of
people with behaviour that differs from those who are generally
poor at taking treatment. Rather than having a chaotic lifestyle
e.g. due to alcohol abuse that results in poor adherence, treatment
interrupters may be generally good at taking treatment but may
experience a single event that results in a treatment interruption.
Both behaviours may result in virological failure.
The mean cumulative adherence in this cohort was high for
both cases (97.8%) and controls (96.6%), as the ART programme
at this site is focussed on adherence support.[19] Failure despite
excellent recorded adherence has been noted elsewhere in sub-
Saharan Africa. [20] When stratified the failures were less
adherent than controls, with 73% of failures having excellent
cumulative adherence (.95%), compared to 84% of controls. This
creates a unique group of patients to study, as despite intense
adherence education, monitoring, intervention, and acceptable
levels of cumulative adherence, we still find individuals who fail
therapy. Treatment interruptions and variations on adherence
may explain some of this, as discussed below, and the use of tablet
counts, which typically over-estimate adherence, may also
contribute. However further adherence and pharmacokinetic
work is needed to explore individuals with discordant adherence
and virological response as treatment scale-up continues [21].
Due to the national protocol for naı ¨ve patients, all started on a
NNRTI-based therapy. The implications of treatment interruption
must be explored with this in mind. NNRTI-based therapy has
been found to have acceptable levels of suppression at moderate
rates of adherence (80%–95%) [2,3,22], with resistance usually
occurring at lower levels of adherence in contrast to protease
inhibitor-based therapy where peak resistance occurs at levels
closer to optimal adherence of .95%. [16] However, abrupt
treatment interruption of NNRTI therapy can be damaging as the
half-life of the NNRTIs is usually longer than that of the
accompanying NRTIs resulting in an unprotected NNRTI tail.
[9,23]. This may provide explanation as to why failure occurred in
interrupters with otherwise excellent adherence.
Adherence fluctuations of .10% were also shown to have a
significant impact on virologic outcomes. Variation was an
absolute difference in adherence by tablet count from one quarter
to the next, and may have occurred despite adequate adherence
during that interval, for example, 93% adherence in one interval
and 103% in the next. This may be due to shorter periods of
treatment interruption (,28days) that were not captured in this
study, but which might have resulted in unprotected exposure of
the NNRTI.
The current literature does not have a standard definition for
the amount of time off treatment that constitutes a treatment
interruption. Different studies use different periods of time, from 3
days to 3 months off treatment.[5–7,24] One of the limitations of
this study is that we were not able to capture short intervals of off-
treatment time due to our dependence on monthly dispensing
records for collection of tablet return and dispensed data. The
intention therefore was to capture a significant time off treatment,
rather than a few missed doses; however, the significant impact of
variation in adherence on treatment outcomes suggests that even
missing a few doses may be relevant to virologic outcomes. Some
of the intervals had missing data, but only a small proportion
(2.7%), and most occurred during a single 6 month period of staff
shortage. Thus most of the missing data was missing at random.
We also had insufficient power to examine effect modification of
TI at different cumulative adherence strata, so, although we know
that TIs have an effect in people with excellent adherence, we
cannot look at the effect in those with poor adherence. Another
Table 2. Cumulative adherence presented as proportion of
patients per adherence category.
Cumulative
Adherence
Total population
(n=244)
Controls
(n=200)
Failures
(n=44) p-values*
,80% 2 (0.8%) 1 (0.5%) 1 (2.3%) 0.088
80%-,90% 12 (4.9%) 7 (3.5%) 5 (11.4%)
90%-,95% 30 (12.3%) 24 (12.0%) 6 (13.6%)
$95% 200 (81.9%) 168 (84.0%) 32 (72.7%)
Data is presented as number of patients per category with percentage i.e. n (%).
*chi square test for differences in proportions.
doi:10.1371/journal.pone.0023088.t002
Table 3. Multivariate logistic regression analysis: association
between adherence variables and failure.
Variable
Univariate
OR(95% CI)
Mulitvariate OR
(95% CI)*
Cumulative adherence of ,95% 2.09 (0.93–4.70) 1.69 (0.71–4.02)
Cumulative adherence of ,90% 4.50 (1.31–15.48) 3.01 (0.81–11.21)
One episode of adherence
variation of .10%
2.07 (1.01–4.24) 2.20 (1.04–4.64)
$1 episodes of treatment
interruption ($28 days)
4.42 (1.67–11.70) 4.01 (1.45–11.10)
$1 episodes of treatment
interruption ($28 days) not
due to toxicity
5.62 (1.76–17.97) 3.90 (1.09–13.92)
$1 episodes of patient initiated
treatment interruption ($28 days)
7.32 (1.30–41.14) 4.40 (0.78–24.93)
*Adjusted for age, sex, baseline CD4 count, baseline viral load.
doi:10.1371/journal.pone.0023088.t003
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calculate patient adherence. Some studies suggest multiple
measures or a composite measure might be a better way to
capture adherence. [25,26] However, in a resource-constrained
busy clinic, tablet counts were the quickest and most affordable
way of calculating adherence, and our results show correlation of
adherence with failure.
The results of this study have several implications for clinical
practice and can provide some simple measures to warn providers
of potential failure. Often adherence studies focus on cumulative
adherence, which can be complex to calculate during a clinic visit,
especially for someone who has been on treatment for some time.
Interval adherence (adherence from previous to current visit) is a
quick and easy measure for clinical or support staff to calculate
and variation from one interval to the next gives warning of
potential failure prior to viral load testing. Furthermore, treatment
interruption is an event that easily identifies an individual as at risk
of failure for the clinical team. This study should alert providers
that treatment interruptions must be avoided even in the most
adherent patients.
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